发明公开
EP1838667A2 2ALPHA-METHYL-19-NOR-1ALPHA-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES
审中-公开
2ALPHA-METHYL-19-NOR-1ALPHA-HYDROXY-HOMOPREGNACALCIFEROL及其用途
- 专利标题： 2ALPHA-METHYL-19-NOR-1ALPHA-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES
- 专利标题（中）： 2ALPHA-METHYL-19-NOR-1ALPHA-HYDROXY-HOMOPREGNACALCIFEROL及其用途
-
申请号： EP05851806.9申请日： 2005-11-18
-
公开(公告)号： EP1838667A2公开(公告)日： 2007-10-03
- 发明人: DELUCA, Hector, F. , SICINSKI, Rafal, R. , PLUM, Lori, A. , CLAGETT-DAME, Margaret , GOWLUGARI, Sumithra
- 申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION
- 申请人地址： 614 Walnut Street, Floor 13 Madison, WI 53705 US
- 专利权人： WISCONSIN ALUMNI RESEARCH FOUNDATION
- 当前专利权人： WISCONSIN ALUMNI RESEARCH FOUNDATION
- 当前专利权人地址： 614 Walnut Street, Floor 13 Madison, WI 53705 US
- 代理机构： McCluskie, Gail Wilson
- 优先权： US630181P 20041122
- 国际公布： WO2006057902 20060601
- 主分类号： C07C401/00
- IPC分类号： C07C401/00 ; A61K31/59 ; A61P11/06 ; A61P17/06 ; A61P35/00 ; A61P29/00 ; A61P37/00
摘要：
This invention discloses 2α-methyl-19-nor-vitamin D analogs, and specifically 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
信息查询
